Comparative Pharmacology
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus HISTAFED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARITIN HIVES RELIEF versus HISTAFED.
CLARITIN HIVES RELIEF vs HISTAFED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inverse agonist at histamine H1 receptors, blocking histamine-mediated effects in allergic reactions.
HISTAFED is a combination of pseudoephedrine, a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors in the nasal mucosa causing vasoconstriction, and triprolidine, a first-generation antihistamine that competes with histamine for H1-receptor sites on effector cells in the gastrointestinal tract, blood vessels, and respiratory tract, thereby preventing histamine-mediated effects.
10 mg orally once daily
60 mg orally every 4 to 6 hours as needed; maximum 360 mg per day.
None Documented
None Documented
8.4 hours (range 3-20 hours) for loratadine; 28 hours (range 8.8-92 hours) for active metabolite desloratadine, allowing once-daily dosing.
3-4 hours for pseudoephedrine component; shorter in children (2-3 h), prolonged in renal impairment
Renal: ~40% as metabolites, <1% unchanged; Fecal: ~40%; Biliary: minor contribution.
Renal (approximately 65% as unchanged drug and metabolites), biliary/fecal (35%)
Category C
Category C
Antihistamine
Antihistamine/Decongestant Combination